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Currently, there is a considerable interest to the assessment of blood-brain barrier (BBB)
development as a part of cerebral angiogenesis developmental program. Embryonic
and adult angiogenesis in the brain is governed by the coordinated activity of
endothelial progenitor cells, brain microvascular endothelial cells, and non-endothelial
cells contributing to the establishment of the BBB (pericytes, astrocytes, neurons).
Metabolic and functional plasticity of endothelial progenitor cells controls their timely
recruitment, precise homing to the brain microvessels, and efficient support of brain
angiogenesis. Deciphering endothelial progenitor cells physiology would provide novel
engineering approaches to establish adequate microfluidically-supported BBB models
and brain microphysiological systems for translational studies.
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CSF, colony-stimulating factor; CXCL12, chemokine (C-X-C-motif) ligand 12; CXCR4, C-X-C chemokine receptor 4; DLL4,
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Neurovascular unit (NVU) consisted of cerebral microvessel
endothelial cells, pericytes, astrocytes, neurons, and microglia
is a structural and functional basis of the blood-brain barrier
(BBB). NVU/BBB is actively involved in the regulation of crucial
physiological processes within the brain, but is dramatically
compromised in almost all the types of brain pathology
(neurodevelopmental disorders, neurodegeneration, trauma,
ischemia, neuroinflammation, neuroinfection etc.).
Brain microvascular endothelial cells (BMEC) represent one
of the most interesting subpopulations of endothelial cells (EC)
due to their specific properties required for the appropriate
functioning of these cells: (i) regulation of cerebral blood
circulation, (ii) selective and controlled permeability of the
blood-brain barrier (BBB). In contrast to endothelial cells of
non-cerebral localization, BMEC are characterized by high
expression of tight junctions, high electrical resistance, low
fenestration, small perivascular space, high prevalence of insulin
and transferrin receptors, relatively big number of mitochondria
(Stamatovic et al., 2008; Salmina et al., 2014). As it was
demonstrated (De Bock et al., 2013), metabolic plasticity of
endothelial cells allows rapid switching to active growth upon
stimulation, i.e., under the conditions supporting establishment
of tip or stalk cells phenotypes with the corresponding
proliferative and migratory activity. Thus, metabolism of
endothelial cells is considered as a major driver of angiogenesis
and might serve as a marker of endothelial dysfunction seen in
cardiovascular and cerebrovascular diseases (Eelen et al., 2015).
However, another question arises on the metabolic activity of
endothelial progenitor cells (EPC) that are responsible for vessel
development and (re)endothelialization.
Currently, there is considerable interest to the assessment
of BBB-related angiogenesis in developing and adult brain.
Development of NVU critically depends on the availability
of EPC that originate from embryonic hemangioblasts and
hematopoietic stem cells and form the primary vascular plexus
(Rae et al., 2011a). Embryonic vasculogenesis and establishment
of BBB is driven by newly formed EPC migrating from the sites
of hematopoietic stem cells (HSC) development. Bone marrow
starts to function as a source of HSC just before birth whereas
in embryogenesis, multi-lineage hematopoietic progenitors exist
in the extraembryonic yolk sac at E8.25, in the placenta and
embryonic aorta-gonad-mesonephros region at E10, and in the
fetal liver at E11.0 in mice (Cos¸kun et al., 2014). Later, in the
postnatal brain, EPC may also come from the bone-marrow
hematopoietic niches, but their role in the endothelialization,
maturation and maintenance of the structural and functional
integrity of BBB is not clear yet.
The term “endothelial progenitor cells” initially covered
various subsets of circulating progenitors derived from bone-
marrow pluripotent stem cells and hemangioblasts. EPC
are involved in vessel development and regeneration, being
recruited from the bone-marrow to the peripheral blood,
displaying immunopositivity for CD34, CD45, CD133, VEGFR2,
c-kit, and, presumably existing as hematopoietic cells with
pro-angiogenic activity in vitro and in vivo (Richardson
and Yoder, 2011; Yoder, 2012). In adults, there are two
origins of EPC: (i) hematopoietic origin (EPC derived from
bone marrow multipotent hemangioblasts [VEGFR2(+)VE-
cadherin(+)CD45(−) and mesenchymal stem cells (MSC)
(CD73(+)CD90(+)CD105(+)CD34(−)CD45(−)]; (ii) and non-
hematopoietic origin (EPC found at the sites of extensive
angiogenesis but demonstrating no signs of hematopoietic origin,
being, probably, derived from tissue multipotent cells) (Chao and
Hirschi, 2010; Leeper et al., 2010; Boxall and Jones, 2012).
Bone-marrow-derived MSC possess the ability to migrate
though the BBB in vivo and in vitro models without evident
alterations in the barrier’s integrity (Matsushita et al., 2011).
Interestingly, there are the reciprocal effects of BMEC and MSC
in hypoxic conditions: BMEC stimulate differentiation of MSC
into EC, whereas MSC stimulate proliferation and migration of
BMEC, thereby contributing to local angiogenesis associated with
high BBB permeability (Liu et al., 2008).
Brain tissue multipotent cells express markers for
mesenchymal stem cells (i.e., CD13, CD105) and pericytes
(i.e., PDGFR-β/CD140b, RGS5, Kir 6.1, NG2) and demonstrate
strong multilineage potential (Paul et al., 2012). Relative
similarity of MSC and pericytes is very well-known. In the adult
brain, pericytes originate from the pre-existing pool or from
some bone-marrow progenitors, may express wide spectrum
of MSC markers in culture (CD44, CD73, CD90, CD105),
contribute to the maintenance of BBB integrity being in the tight
contact with EC (Pombero et al., 2016). Pericytes and endothelial
cells are under the control of perivascular astrocytes that induce
their differentiation needed for effective angiogenesis, thereby
astroglial dysfunction may affect angiogenesis via dysregulation
of EPC/EC/pericytes interactions in cerebral microvessels. In
several tissues, aberrant angiogenesis may be caused by the loss
of pericytes number and inadequate proliferative response of EC
(Ergul et al., 2015).
Thus, vasculogenesis (establishment of new vessels) is
provided by EPC differentiated from embryonic hemangioblasts,
or adult EPC, multipotent stem cells, and vessel wall-associated
mesenchymal-like cells (mesoangioblasts) (Schmidt et al., 2007).
Also, adult hemangioblasts have been detected in the CD133+-
population of peripheral blood (Loges et al., 2004). Sprouting or
splitting angiogenesis (adult vascular growth) is provided by EC
pre-existing in the vessel wall, but acquiring new phenotype (tip
and stalk cells) and acting with the support of EPC coming from
bone marrow or non-hematopoietic sources (Rae et al., 2011b),
and pericytes.
In pathological conditions, angiogenesis and vascular
remodeling are usually considered as significant components
of brain tissue repair program after injury (hypoxic, ischemic,
traumatic, inflammatory, toxic etc.), thus, EPC-mediated
mechanisms should be of great importance. As an example,
in stroke models, mobilization of EPC from bone marrow
correlates to the severity of cerebral alterations (Arai et al., 2009).
In Alzheimer’s type of neurodegeneration, accumulation of
amyloid results in excessive angiogenesis and leaky BBB whereas
the levels of circulating EPC is dramatically reduced (Lee et al.,
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2009; Biron et al., 2011). In autism, persistent remodeling of brain
microvessels with the characteristics of splitting angiogenesis
due to predominant proliferation of pericytes but not EC may
affect neuronal connectivity (Azmitia et al., 2016). In diabetes
mellitus, cerebral angiogenesis is exclusively enhanced and is
associated with the appearance of non-functioning microvessels
and decreased ratio of pericytes to EC (Prakash et al., 2012),
but hypoxic injury of diabetic brain is characterized by delayed
angiogenesis impeding brain tissue repair (Poittevin et al.,
2015). In depression, insufficient angiogenesis is caused by the
decreased number of EPC in the peripheral blood, low VEGF
effects, and elevated levels of anti-angiogenic factors, whereas
stimulation of cerebral angiogenesis is a marker of functional
recovery (Boldrini et al., 2012; Yamada, 2016). In sum, it is
clear that in almost all the types of brain pathology, deficits
of circulating EPC attribute to the aberrant angiogenesis, thus
suggesting impaired mobilization, migration of these cells to the
brain.
Chemokines-, SDF1-, MMP9-, VEGF-, NO-dependent
mechanisms are responsible for the mobilization of EPC from
the bone marrow, whereas homing of the recruited cells is
provided by molecules with high pro-angiogenic potential (i.e.,
VEGF, IGF, angiopoietins, cytokines, integrins) at the sites of
developmental or pathological angiogenesis (Tilling et al., 2009;
Caiado et al., 2011). Also, in addition to bone marrow-derived
EPC, non-bone marrow-derived cells (tissue resident) could
transform to EC and take part in the re-endothelizlization and
angiogenesis (Balaji et al., 2013).
According to the current view, circulating EPC may
differentiate into EC to restore the endothelial layer, may
directly incorporate into injured endothelium, or may secrete
pro-angiogenic factors (VEGF, SDF-1, PDGF etc.) or release
microparticles to stimulate tip and stalk cells (Li et al., 2015b).
Arrival of EPC to the sites of angiogenesis results in the
establishment of functional connections between EPC and EC
through the coordinated expression of adhesion proteins in a
TNFα-dependent manner (Prisco et al., 2015). EPC provide
paracrine signaling to facilitate angiogenesis and phenotype
changes in the pre-existing resident endothelial (or endothelial
progenitor) cells in the tissue-specific manner at the sites of
endothelial injury or high metabolic demand (Zhang et al.,
2014). Either in embryonic and adult EPC, secretion of pro-
angiogenic chemokines is up-regulated by hypoxia simulating
in greater expression of CXCR4, CXCR2, and release of
CXCL1, CXCL12, macrophage migration inhibitory factor MIF,
VEGF. As a result, adhesive capacity of EPC and local tube
formation are greatly improved (Kanzler et al., 2013). Thus,
EPC whose recruitment from the bone marrow is stimulated
by hypoxia or cytokines, serve as cellular carriers of angiogenic
regulatory factors instructed to promote angiogenesis or re-
endothelialization. Such carrier function of EPC is compromised
in aging as it was demonstrated on the reduced secretion of
VEGF, IL-8, IL-17, and granulocyte-colony stimulating factor
(G-CSF) from elderly human EPC (Kushner et al., 2008).
Recent data suggest that this mechanism seems to be
supplemented with the complementary ones. Firstly, there is a
transfer of organelles (i.e., mitochondria, lysosomes) through
active tunneling nanotubes from circulating EPC [that should be
very prone to initiate nanotubes activity similarly to other stem
cells (Yang et al., 2016)] to the resident EC (de Cavanagh et al.,
2014). Such organelle donation may rescue damaged endothelial
cells from apoptosis or, conversely, facilitate active cell death and
establishment of a platform for further endothelial replacement.
As an example, in the senescent stressed endothelium, lysosomal
transfer from EPC improves EC viability, normalizes endothelial-
regulated vasorelaxation, and reduces programmed cells death
(Yasuda et al., 2011). Secondly, EPC-released membrane-derived
microvesicles are responsible for mRNA transfer to EC. To do
that, the microvesicles incorporate in EC due to intermolecular
interaction of EC proteins with α4 and β1 integrins (Very
Late Antigen-4, VLA-4) expressed in microvesicles, thereby
promoting EC proliferation, tube formation, and reducing EC
apoptosis (Deregibus et al., 2007). It should be mentioned
that α4β1 integrins are the receptors for fibronectin and
VCAM-1, and the latter is important for BBB functioning in
neuroinflammation (O’Carroll et al., 2015).
General population of EPC is very heterogenous and dynamic.
Bone marrow hemangioblasts-derived early and late EPC might
be determined in vitro being different in their ability to form
new vessels and to incorporate into growing vascular networks:
Late CD31(+)VE-cadherin(+)CD34(+)CD14(−)CD45(−) EPC
with high expression of eNOS and VEGFR2 but not early
CD31(+)VE-cadherin(−)CD34(−)CD14(+)CD45(+) EPCwith
low expression of eNOS and VEGFR2 (Fadini et al., 2012;
Cheng et al., 2013; Minami et al., 2015). Expression of eNOS
is critical for EPC proliferation and migration (Lu et al., 2015)
and may contribute to controlling viability of EPC at the sites
of induced angiogenesis (Dong et al., 2016). Transcriptomic data
confirmed that early EPC are hematopoietic cells with monocytic
phenotype and low angiogenic potential, whereas late EPC have
greater proliferative potential and high expression of VEGFR2
(Medina et al., 2010) that is ultimately involved in various steps
of angiogenesis and is up-regulated in EPC expansion (Smadja
et al., 2007). Interestingly, differential expression of VEGFR2
and another universal EPC marker—Tie2—correlates to the
ability of EPC to promote angiogenesis: high Tie2 expression
is required for re-endothelialization, whereas greater number of
low Tie2/high VEGFR2 cells better incorporate into CD31(+)
capillaries (Adamcic et al., 2013).
Cell adhesion glycoprotein CD146 is a pan-endothelial marker
found in EPC, circulating EC, and in murine brain blood vessels
(Schrage et al., 2008; Flores-Nascimento et al., 2015). CD146(+)
EPC belong to the group of late EPC with high pro-angiogenic
potential. These EPC could be easily distinguished from
CD146(+) circulating mature EC: CD146+ CD34+ CD45+
CD133+ or CD117+, and CD146+ CD34+, CD45– CD133–
or CD117–, respectively (Delorme et al., 2005). Moreover,
proteolytically generated soluble form of this molecule (sCD146)
possesses pro-angiogenic activity (Stalin et al., 2013). The exact
role of CD146 expressed in cerebral endothelium remains to be
evaluated, however, it takes part in the mechanism of lymphocyte
extravasation through the BBB in neuroinflammatory conditions
(Duan et al., 2013).
Some bone marrow-derived EPC express stem cells marker
CD117 (c-kit) (Beaudry et al., 2007) which is involved in MMP9-
mediated mobilization of EPC from the bone marrow in a
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response to high concentrations of VEGF (Heissig et al., 2003),
and CXCR4 which is a receptor for CXCL12 chemokine (stromal
cell-derived factor-1, SDF-1) involved in the process of EPC
mobilization to the peripheral blood. Bone marrow-derived and
umbilical cord blood-derived EPC differ in CXCR4 expression
even they demonstrate compatible angiogenic properties (Finney
et al., 2006).
Increased expression of CXCR4 on EPC is required for
adenosine-induced mobilization of these cells from the bone
marrow (Rolland-Turner et al., 2013). The remarkable fact
is that mature BMEC are also regulated by adenosine which
is known as a mediator of BBB structural and functional
integrity: acting at A2A adenosine receptors it increases the
barrier permeability for some drugs and immune cells for
the meaningful time window (Carman et al., 2011; Kim and
Bynoe, 2015), therefore being suggested as a potent agent
for improving drug delivery to the CNS (Gao et al., 2014).
Adenosine in high concentrations is produced in various tissues
from ATP by CD39/CD73 ectonucleotidases or, alternatively, via
CD38 (or CD157)/CD203a/CD73 pathway sensitive to the local
concentrations of NAD+ (Horenstein et al., 2013). Bone marrow
clonogenic niches are enriched in such enzymatic activities
(Quarona et al., 2015), however, it remains to be assessed whether
similar mechanism is active at NVU/BBB. At least, very recent
hypothesis announced in (Panfoli et al., 2016) stated that elevated
levels of adenosine in the brain and blood due to endothelium-
driven metabolism of ATP to adenosine in premature infants
might be a biomarker of prematurity risk.
Circulating EC might be found in the peripheral blood due
to endothelial injury, anoikis, or apoptosis. These cells express
the markers of mature differentiating EC (i.e., CD31 and vWF
but not CD133), and could also contribute to vascular repair
(Tenreiro et al., 2016). Genomic studies revealed that expression
patterns of RNAs and miRNAs in EPC and EC are different and
reflect significant changes in the functional role of these two
types of cells in development and maintenance of endothelium
competence (Cheng et al., 2013; Chang et al., 2014).
Pericytes surrounding and supporting endothelial cells share
some common properties with EPC (or with bone marrow
stromal cells, BMSC): expression of adhesion molecules and
VEGFR2, angiopoietin signaling, and prominent pro-angiogenic
potential (Bagley et al., 2005; Winkler et al., 2014; Cantoni et al.,
2015). That is not surprising due to bone marrow origin of
pericytes (Lamagna and Bergers, 2006) and their potential to
differentiate into various cell types or to originate from early
EPC in vitro (Cantoni et al., 2015). Moreover, co-culture of EPC
and bone marrow-derived stem cells in vitro (mesenchymal stem
cells) results in the appearance of pericyte-like cells due to ability
of bone marrow-derived stem cells to differentiate into pericytes
with the paracrine regulatory activity of EPC (Loibl et al., 2014).
In the context of BBB, pericytes origin and functioning are of
great importance due to higher (10–30-fold) pericyte/endothelial
cell ratio in the central nervous system (CNS) comparing to other
tissues (Winkler et al., 2014).
Aberrant physiology of EPC is tightly implicated in the
pathogenesis of various types of pathologies associated with
endothelial dysfunction and vasculopathy including diabetes
mellitus, Alzheimer’s disease, cerebrovascular and cardiovascular
diseases etc. (Lee et al., 2010; Brea et al., 2011; Yiu and Tse,
2014; Berezin and Kremzer, 2015). Circulating CD146(+) EPC
as well as BMEC have been proposed as novel biomarkers of
BBB impairment in neuroinfection and neurotoxicity (Huang
et al., 2013a) applicable for diagnostic purposes. At the same
time, there is a growing evidence that EPC might serve as a
therapeutic tool for a number of CNS pathologies including
stroke, neurodevelopmental disorders, and neurodegeneration
(Castillo-Melendez et al., 2013; Fukuda et al., 2013; Zhao
et al., 2013). Very promising data have been obtained in the
application of EPC for BBB repair in vivo (Huang et al., 2013b).
However, application of EPC into routine neurological clinical
practice is hampered by poor understanding the mechanisms
underlying EPC homing at CNS and EPC-mediated cell-to-cell
communications in cerebral microvessels within the NVU.
Migration of EPC to the BBB is dictated by numerous
factors contributing to elevated permeability of BBB that
might serve as signals for EPC mobilization and moving
toward the brain tissue. Studying brain angiogenesis and BBB
establishment and maturation (so-called barriergenesis) offers
some unique opportunities to distinguish a role for EPC in either
developmental or pathological angiogenesis since both these
processes have different mechanisms and functional significance
for the developing, mature and aging brain (Vallon et al., 2014).
Metabolic activity of EPC and related cells with pro-angiogenic
potential is not well-studied yet. There is no doubt that
metabolism of EPC and metabolic microenvironment at the sites
of their destination affect efficacy of angiogenesis. As an example,
remodeling of primary capillary plexus and vasculogenesis
during embryogenesis depend on the actual metabolic demands
of the defined tissue (Yoder, 2012). Particularly, EPC metabolic
activity in the resting state and upon stimulatory conditions
(i.e., expansion in the bone marrow, mobilization, and targeted
migration) differs. The same should be true for BMEC activated
in angiogenesis and converted to tip or stalk phenotype.
Thus, it is reasonable to propose that local microenvironment
in the bone marrow supporting EPC maintenance, expansion,
and mobilization would have some similarities with the
microenvironment providing within the NVU to support BMEC
functional activity, BBB establishment and repair. Since elevated
permeability of BBB is associated with the establishment of sites
of active neurogenesis (Lin et al., 2015b), migration of EPC
from the hematopoietic tissue to the adult BBB is a transfer
from one clonogenic niche to another one. Upon coming to
the brain microvessels, EPC incorporate in the endothelial
layer or serve as a source of pro-angiogenic molecules in a
way similar to pericytes and perivascular astrocytes, thereby
establishing appropriate conditions for branching angiogenesis,
restoration of BBB structural and functional integrity, and
reparative neurogenesis (Figure 1).
Angiogenesis consists of cell proliferation, vessel sprouting,
establishment of anastomosis, pruning and remodeling,
acquisition of endothelial quiescence (Ehling et al., 2013).
Antigenic and functional heterogeneity of endothelial
progenitors determines the mechanisms of EPC-supported
angiogenesis. In the brain, vascularization mainly occurs
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FIGURE 1 | Mobilization and homing of EPC to the injured brain tissue. Within the NVU, pericytes and perivascular astrocytes produce the molecules with
pro-angiogenic properties upon neuronal overexcitation, hypoxic or ischemic brain injury, BBB dysfunction, or neuroinflammation. Bone marrow stromal cells secrete
various factors contributing to maintenance or expansion of EPC when needed. In a quiescent state, EPC have high glycolytic activity due to relatively hypoxic
micronevironment within the clonogenic niche. Being activated by cytokines, chemokines, growth factors whose systemic and local concentrations are elevated due
to brain injury, EPC up-regulate metabolic pathways for effective energy production (glycolysis, mitochondrial respiration, fatty acid oxidation). Generation of ROS is
enhanced as a side-effect of mitochondria activation, but is counteracted by well-established antioxidant machinery in EPC. Homing of recruited EPC to cerebral
microvessels is driven by cytokine-, chemokine-, and integrin-based mechanisms. Upon arrival at the site of BBB disruption, EPC release pro-angiogenic factors and
membrane vesicles enriched with EPC-specific proteins and mRNA (A); incorporate into the endothelial layer or donate organelles to the stressed EC (B). These
mechanisms lead to the stimulation of branching angiogenesis associated with the activation of tip and stalk EC, and re-establishment of BBB.
through angiogenesis (Grant and Janigro, 2006), therefore
different populations of cells involved into angiogenic events
contribute to the initiation of vessel growth, destabilization of
extracellular matrix, establishment of novel microvessels and
their maturation (Figure 2). In the context of BBB, the latter
stage is corresponded to the maturation of the barrier and
acquisition of adequate selective permeability and transporting
activity. Presumably, all the earlier steps of angiogenesis are
coupled with the elevated permeability of the BBB. Therefore, a
reasonable question is how all these processes are linked to the
metabolic plasticity of endothelial progenitors and other cellular
components of the NVU (neurons and glia)?
OXIDATIVE METABOLISM OF
PROGENITOR ENDOTHELIAL CELLS AND
METABOLIC STATUS OF BRAIN TISSUE:
COMPLEMENTARY FEATURES
Developmental angiogenesis and, probably, neuroplasticity-
associated angiogenesis, are mainly regulated by local production
of pro-angiogenic molecules (VEGF, TGFβ) and corresponding
changes in the metabolism, proliferation, and differentiation
status of migrating EPC governed byWnt/β-catenin- and Notch-
signaling (Vallon et al., 2014). In pathological angiogenesis
associated with brain injury, the main stimuli provoking
re-endothelialization are neuroinflammatory mediators (i.e.,
cytokines, growth factors) as well as hypoxia/ischemia-
induced changes in the tissue metabolism that mobilize EPC
from bone marrow and attract them to the brain tissue.
As an example, membrane-bound Kit-ligand expressing on
microvascular EC at the sites of inflammation provide effective
homing of EPC to the activated endothelium (Dentelli et al.,
2007).
It is reasonable to assume that neuroplasticity-associated
angiogenesis might critically depend on the local branching
provided by pre-existing BMEC acquiring tip or stalk phenotype,
whereas developmental and pathological angiogenesis would
require extensive mobilization and homing of bone marrow-
derived endothelial progenitors. It is still under the debates which
local metabolic factors in the brain are attributed to homing
of EPC to the brain and their integration into the developing
cerebral microvessels, or how it is corresponded to the metabolic
pattern of EPC.
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FIGURE 2 | Participation of different types of EPC in adult brain angiogenesis. In the adult brain, EPC originated from the bone marrow multipotent
hemangioblasts and MSC, or from the multipotent mesenchymal-like and pericyte-like cells located in cerebral microvessels, give rise to the population of EPC which
is able to activate BMEC, to integrate into the endothelial layer, and to promote recruitment and proliferation of pericytes upon the action of pro-angiogenic stimuli.
Later, perivascular cells coordinate acquisition of endothelial quiescence and vessel maturation.
Metabolic Plasticity of EPC
One of themost potent local regulators of angiogenesis is hypoxia
and associated metabolic events, particularly, stimulation of
glycolysis. At the same time, lactate as the end-product of
glycolysis has multiple functions in the brain being involved
in the coordination of neuron-astrocyte metabolic coupling
and gliovascular control of local blood flow (Mosienko et al.,
2015; Kasparov, 2016). There is an accumulating evidence for
glycolysis-mediated control of BBB development and functional
activity (Salmina et al., 2015). EPC like other stem/progenitor
cells are characterized by active glycolysis and high production of
lactate (Goligorsky, 2014). When resident tissue BMEC acquire
tip cell phenotype, glycolysis is also intensified (Stapor et al.,
2014). In the BBB, expression of endothelial MCT1 transporting
ketone bodies, pyruvate, and lactate is maximal in the perinatal
period followed by dramatic decrease in first 1 week of postnatal
life with the corresponding switch to prevailed expression of
GLUT on endothelial cells and MCT1 on astroglial cells at the
postweaning period in rodents (Vannucci and Simpson, 2003).
Such developmental changes reflect predominant consumption
of lactate and ketone bodies or glucose in fueling the developing
and maturing brain, respectively. Thus, EPC migrating to
cerebral microvessels in perinatal and early postnatal period
appear in the microenvironment of excessive lactate and ketone
bodies utilization. However, such proposal requires further
assessment since recent transcriptome study has shown that
MCT1 is expressed at lower levels in the embryonic choroid
plexus (E15) than in the adult brain, whereas GLUT1 is expressed
in an opposite manner (Saunders et al., 2013, 2015).
High-energy metabolites lactate and ketone bodies are known
as promotors of stem cells or cancer cells growth and best
“mitochondrial fuels” for actively-proliferating cells. To achieve
such effects of lactate and ketone bodies, the target cells should
express MCT1 for effective import of these metabolites and
their utilization in the intracellular pathways (Curry et al.,
2013). One of the possible explanations of this phenomenon
was already given (Martinez-Outschoorn et al., 2011): both
these metabolites increase the pool of acetyl-CoA, leading to
increased histone acetylation and elevated gene expression. These
authors suggested that since the brain is a particularly lactate-rich
microenvironment due to lactate-producing activity of astrocytes
in a close vicinity to active neurons (so-called astrocyte-neuron
metabolic coupling), metastatic cancer cells may be attracted to
the lactate-richmicroenvironment of the brain. Similar reasoning
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shows that this might be true for EPC migrating to developing
BBB where lactate and ketone bodies levels are rather high due
to extensive expression of their transporters at the endothelial
layer and great dependence of developing brain on these energy
substrates. Taking into the consideration the enrichment of
BBB endothelial cells with mitochondria comparing to EC in
other tissues (Oldendorf et al., 1977), and obvious coupling of
mitochondrial biogenesis to angiogenesis (De Bock et al., 2013),
it is reasonably to propose that high expression of MCT1 in
endothelial BBB cells as well as activation of astrocytic glycolysis
and release of lactate at the prenatal and early postnatal period
would provide the microenvironment adequate for homing and
local proliferation of EPC. It is interesting that EPC as well
as mature EC demonstrate the compatible rate of proliferative
activity in vitro, and the number of mitochondria which is less
in EPC at the beginning of cell culture is very rapidly elevated to
support proliferative activity (Rae et al., 2011a).
Utilization of ketone bodies leads to elevating acetyl-
CoA and depleting NAD+ levels in the cells (Newman and
Verdin, 2014). Thus, availability of NAD+ for the activity
of NAD+-converting enzymes like NAD+-glycohydrolases
(polyADP-ribosyl polymerase, ADP-ribosyl cyclase, monoADP-
ribosyl transferases) or NAD+-dependent deacetylases (sirtuins)
is reduced. The latter might result in higher levels of
histone acetylation and maintenance of transcriptionally active
chromatin in the cells.
Thus, EPC and newly-formed BMEC in the embryonic
or early postnatal BBB might be characterized by consuming
of ketone bodies and lactate, considerable mitochondrial
activity, intracellular depletion of NAD+, suppression of histone
deacetylation, and activation of gene transcription. In accordance
with this metabolic pattern, we may propose that when BBB
starts expression of GLUT for predominant consumption of
glucose for NVU metabolic needs, glycolytic flux is activated
as much as possible in BMEC, NAD+ is effectively regenerated
due to pyruvate to lactate conversion, and NAD+ is easily used
by NAD+-glycohydrolases or stimulates deacetylase activity.
Probable involvement of NAD+-glycohydrolases (i.e., CD38)
abundantly expressed in activated astroglial cells (Banerjee et al.,
2008; Salmina et al., 2009) in the establishment of pro-angiogenic
brain microenvironment might be suggested by analogy with the
mechanism recently proposed in (Horenstein et al., 2015).
Notch signaling is one of the key regulators of oxidative
cell metabolism: high proliferative potential of tumor cells
corresponds to hyperactive Notch, suppression of glycolysis
and preserved mitochondrial activity, whereas low proliferative
potential is attributed to hypoactive Notch, suppressed glycolysis
and attenuated mitochondrial respiration (Landor et al.,
2011). During embryogenesis, Wnt/β-catenin up-regulates Dll4
transcription and strongly increases Notch signaling in the
endothelium, whereas excessive Notch activity results in vascular
abnormalities (Corada et al., 2010). Notch signaling is a
key regulator of vessel maturation and quiescence in the
retinal vasculature: Dll4-Notch signaling supports the quiescent
endothelial phenotype up to P28 (Ehling et al., 2013), promotes
stalk phenotype of EC and results in less number of tip cells and
fewer vessel branches. As expected, inhibition of Notch (i.e., with
a gamma-secretase inhibitor) stimulates angiogenesis (Hellström
et al., 2007). In endothelial cells, diminished Notch activity
due to sirtuin-mediated deacetylation results in excessive vessel
branching (Guarani et al., 2011). Whether analogous mechanism
is true for EPC remains to be assessed but some data might
confirm this proposal: Proteomic and functional analysis has
revealed that Notch signaling is required for EPC functioning and
angiogenesis (Karcher et al., 2015), but slight reduction of Notch
signaling promotes EPC activity and reduces EPC apoptosis
(Ii et al., 2010). Presumably, this bidirectional effect is linked
to EPC heterogeneity: Notch signaling regulates EPC functions
differentially in early (stimulation of cell proliferation, migration)
and late—more matured—EPC (suppression of cell proliferation,
migration, and vessel sprouting) (Chen et al., 2012).
In actively proliferating cells, Wnt-signaling serves as a
positive regulator of glycolysis (Pate et al., 2014). It should be
mentioned that activation of Wnt/β-catenin signaling pathway
in mature brain endothelial cells results in up-regulation of
MCT1 expression, whereas inhibition of gamma-secretase and
corresponding suppression of Notch signaling reduces Wnt/β-
catenin effects on MCT1 expression (Liu et al., 2016). So,
MCT1 expression in BMEC critically depends onWnt/β-catenin-
and Notch-signaling, and the same is true for GLUT1 and
claudin-5 expression in the BBB (Vallon et al., 2014). Among
other regulators of MCT1 in BMEC are cAMP-generating
intracellular signaling pathways (cAMP induces phosphorylation
and internalization of MCT1 proteins) (Smith et al., 2012) and
intracellular pH (acidic pH inhibits while alkaline pH activates
MCT1 activity) (Uhernik et al., 2011). The same Wnt-signaling
pathway is critical for the generation of EPC from pluripotent
stem cells (Lian et al., 2014) that might be under the control
of oxygen availability and HIF-1 activity in undifferentiated
cells: low oxygen concentrations in clonogenic niches result in
the stabilization of HIF-1 followed by the activation of Wnt-
signaling (Mazumdar et al., 2010; De Miguel et al., 2015). Thus,
it is not surprising that next step in the development of EPC
into EC is controlled by Wnt-signaling as well: over-expression
of HIF-1 in EPC promotes EPC proliferation, migration, and
differentiation to EC with clearly distinguishable endothelial
phenotype CD31(+)VEGFR2(+)eNOS(+) (Jiang et al., 2008).
Therefore, high proliferative and pro-angiogenic potential of
EPC is equivalent to high HIF-1 activity (due to relative oxygen
deficits in clonogenic niches either in bone marrow or in
the developing brain), activated Wnt-signaling, and prominent
MCT1 expression in these cells.
Actually, this mechanism seems to be very similar to the so-
called “reverse Warburg effect” proposed for some tumor cells.
It is well-known that Warburg effect is driven by the modulation
of Wnt-signaling: suppression of Wnt leads to reduced glycolytic
flux, andMCT1 appears to be one of the targets (Pate et al., 2014).
This mechanism helps the cells to direct pyruvate from TCA to
LDH-mediated conversion to lactate followed by its release from
the cells. Similar mechanism has been proposed as a basis for
tumor-directed establishment of microenvironment supporting
tumor growth. According to this idea, tumor cells make the
surrounding stromal or endothelial cells more glycolytic via
stabilization of HIF-1 for effective generation of lactate (and,
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probably, ketones and pyruvate) and its export for feeding
the tumor cells equipped with MCT1. The same effect has
been attributed to the mechanisms of tumor neoangiogenesis:
Tumor cells stimulate endothelial cell migration, tube formation,
and tumor angiogenesis through the induction of HIF-1 in
endothelial cells (Doherty and Cleveland, 2013) due to HIF-1α
stabilizing activity of released lactate (De Saedeleer et al., 2012).
In the developing BBB, the main source of lactate is astroglia
surrounding endothelial layer (Salmina et al., 2015), therefore
establishment of high local concentrations of lactate may provide
the microenvironment optimal for EPC migration and EPC
differentiation toward BMEC. Taking into the consideration
the stimulatory effect of lactate on EPC mobilization in vitro
(Milovanova et al., 2008a), we may assume that high local lactate
concentrations established in bone marrow or in the perivascular
space of BBB are the prerequisite for effective participation of
EPC in brain angiogenesis.
Release and utilization of lactate is coordinated by MCT
expression which is a target for CD147-mediated control. CD147
(extracellular matrix metalloproteinase inducer EMMPRIN, or
basigin) is one of the well-known inducers of angiogenesis
contributing to the following processes: (i) lactate utilization in
the cells due to action of CD147 as a chaperone for MCT1
and MCT4 lactate transporters to facilitate their membrane
expression; (ii) glucose uptake through CD147 interaction with
GLUT1; (iii) amino acid transmembrane transport due to
functional association of CD147 with CD98 (Xu and Hemler,
2005; Muramatsu, 2016). Role of CD147 in angiogenesis is
further confirmed by its interactions and stimulatory action on
MMP and VEGFR2 (Bougatef et al., 2009) that might have an
importance for the recruitment of responding subpopulation
from the bone marrow (Chen et al., 2015). It was recently shown
that cyclophilin A which is one of CD147 ligands in various
tissues acts on CD117 (c-kit)–immunopositive bone-marrow
progenitors, thereby contributing to angiogenesis (Perrucci et al.,
2016). Proteomic analysis of EPC revealed expression of CD147
protein (Kaczorowski et al., 2013). On other hand, CD147 is
highly expressed in the capillary endothelium in the CNS being
known as neurothelin for a long time (Kaushik et al., 2015).
Moreover, it was proposed as an earliest molecular marker
for endothelial cells that will form the blood-brain barrier
(Schlosshauer and Herzog, 1990) whose expression is positively
regulated by neighboring astroglia (Janzer et al., 1993). This may
seem paradoxical that recent “renaissance” in CD147 studies
mainly relates to tumor cells oxidative metabolism or tumor-
induced angiogenesis, but not to the role of CD147 in the BBB. In
sum, it is evidently necessary to assess whether CD147 expressed
in EPC and BMEC might serve as a regulator of local pro-
angiogenic microenvironment within the bone marrow and the
BBB.
A shift in perspective is needed when we are talking about
biological role of glycolysis in progenitor cells. It is clear that
glycolytic activity determines not only lactic acid production
but is also responsible for maintaining NAD+/NADH ratio
due to pyruvate-lactate conversion at the final step of the
process. According to this view, NAD+ regeneration at
this stage contributes to intracellular NAD+ pool, thereby
providing indirect regulatory action on NAD+-consuming (i.e.,
NAD+-glycohydrolases) and NAD+-dependent (i.e., sirtuins)
mechanisms (Salmina et al., 2012).
Stem and progenitor cells seem to be critically depended on
NAD+ levels, and NAD+ deficit results in loss of self-renewal
capacity or impairment of differentiation. Many metabolic
processes are very sensitive to changes in NAD+ bioavailability,
i.e., chromatin acetylation/deacetylation, oxidative metabolism,
intracellular calcium mobilization, and calcium-dependent
processes (migration, adhesion, programmed cell death etc.).
We may apply those considerations to some of the mechanisms
linking NAD+ and functional activity of EPC as shown below.
NAD+ Levels and Progenitor Cells
Functioning
Mobilization of EPC from the bone marrow in vivo, their
migration, proliferation and angiogenic activity in vitro can
be inhibited by suppressing the activity of nicotinamide
phosphoribosyltransferase (NAMPT) which is the key
enzyme for NAD+ synthesis, whereas overexpression of
NAMPT led to a SIRT1-depedent enhancement of Notch-1
intracellular domain (NICD) deacetylation, inhibition of Notch
signaling, up-regulation of VEGFR2 and VEGFR3 expression,
and neovascularization (Wang et al., 2014). Depletion of
intracellular NAD+ levels is associated with EPC impairment
in diabetic patients, whereas restoring NAD+ pool rescued
EPC mobilization due to stromal cell-derived factor-1α (SDF-
1α)-mediated events and eNOS expression in EPC (Wang
et al., 2016). So, it is quite clear that effective angiogenesis
requires high intracellular NAD+ levels in EPC and, presumably,
in BMEC. However, very recent data suggest that in some
tissues, NAD+ synthesis might be positively regulated by
the proliferator-activated receptor gamma coactivator-1α
(PGC-1α) (Tran et al., 2016). At the same time, PGC-1α is
a well-described regulator of mitochondrial biogenesis due
to activation of PPARγ and a wide spectrum of transcription
factors. In a case of angiogenesis demand, EPC in the peripheral
blood as well as endothelial cells in tissue elevate expression
of PGC-1α resulting in the activation of Notch signaling and
suppression of EPC migration, inhibition of angiogenesis and
re-endothelialization (Sawada et al., 2014). Nevertheless, there
is no contradiction here, because intracellular NAD+ levels
represent very labile and compartment-specific parameter.
Therefore, it is reasonably that dynamic changes in NAD+
bioavailability due to glycolytic flux, mitochondrial activity and
utilization of NAD+ as a substrate for enzymatic conversion
differentially affect SIRT1/Notch-machinery in EPC. In addition,
as we discussed above, NAD+-sensitive pathways (i.e., local
production of adenosine in the bone marrow or, presumably,
at the BBB) might contribute to the regulation of EPC fate and
BMEC activity.
NAD+ Levels and Progenitor Cells
Senescence
Stem/progenitor cells in general, and EPC, particularly,
undergo process of cellular senescence being subjected to
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inappropriate conditions triggering accumulation of genetic
defects, inactivation of telomerase activity, pro-apoptotic
changes, depletion of total and mitochondrial NAD+ pools,
whereas restoration of NAD+ levels postpones senescence-
associated changes (Zhu et al., 2006; Kushner et al., 2011; Son
et al., 2016; Zhang et al., 2016).
AMP-activated protein kinase (AMPK) appears to be a good
candidate for linking oxidative metabolism and NAD+ levels
in EPC. Upon activation, AMPK promotes ATP-generating
processes (i.e., glycolysis, fatty acid oxidation) and inhibits
ATP-consuming processes (i.e., biosynthesis). In general, AMPK
activity results in elevating the intracellular NAD+ levels
(Cantó et al., 2009). In relation to foregoing effects of
CD147 on EPC, we should mention that AMPK activity
is in the tight functional connection with CD147-CD98hc
complex in actively proliferating epithelial cells: loosening
CD147-CD98hc complex leads to the suppression of cell
proliferation and activation of AMPK (Xu and Hemler,
2005).
Recent data reveal pro-angiogenic effect of AMPK activator
cilostazol either in EPC or EC (Tseng et al., 2016). It is interesting
to mention that activation of AMPK and sirtuin 1 might be also
achieved by the anti-diabetic drug metformin, caloric restriction,
physical exercise, or resveratrol. The latter one induces
NAD+- and PGC-1α-dependent enhancement of mitochondrial
function and mitochondrial biogenesis in muscle cells (Price
et al., 2012). Experimental data suggest that this AMPK-
related mechanism might be, at least partially, responsible for
well-known numerous positive effects of resveratrol on EPC
proliferation, differentiation, their contribution to angiogenesis,
and prevention of cellular senescence due to telomerase
activation (Wang et al., 2007; Xia et al., 2008; Campagnolo
et al., 2015), pro-reparative effect of physical exercise on
EPC mobilization (Kazmierski et al., 2015), and metformin-
induced normalization of EPC differentiation (Li et al., 2015a).
Related mechanism seems to be actual for EC derived from
induced pluripotent stem cells (Jiang et al., 2015). In the
context of BBB, overexpression of AMPK in BMEC preserves
the structural and functional integrity of the barrier in
neuroinfection (Zhao et al., 2014). The same is true for
the effect of resveratrol on BBB in neuroinflammation in
vitro (Hu and Liu, 2016), or for the effect of metformin
on BBB in ischemic brain in vivo (Liu et al., 2014). But it
remains unclear how AMPK activity might contribute to EPC
homing at CNS, and barriergenesis. Moreover, in the more
complicated multicellular systems, effects of AMPK activators
might be quite different as it follows from the recent data
on both positive and negative (time of application-dependent)
effects of AMPK activation on neuronal survival in neonatal
hypoxic-ischemic brain injury (Rousset et al., 2015) This
finding emphasizes the importance of evaluating the presumable
neuroprotective activity of any drug-candidate in ontogenetic
aspect and in the context of cell-to-cell communications within
the NVU.
Table 1 summarizes general metabolic characteristics of EPC
in comparison to EC and BMEC.
MICROPHYSIOLOGICAL SYSTEMS AND
MICROFLUIDICS-BASED BBB MODELS IN
VITRO: APPLICATION OF EPC
Development of relevant blood-brain models in vitro is
one of the topic problems in modern neurobiology and
neuropharmacology. The “ideal” model should match the
following criteria: (i) combination of minimally required cell
types critical for structural and functional BBB integrity;
(ii) reconstruction of the key mechanisms responsible for
selective permeability of the BBB; (iii) long-term preservation of
functional and structural integrity during the model culturing in
vitro; (iv) reproduction of specific properties of the defined cell
population within the model in (patho)physiological conditions;
(v) relative simplicity of assembling the barrier and assessment of
its permeability.
Among all the approaches proposed to achieve the above-
mentioned goals, using the stem cell-derived components of
the BBB in the models in vitro appears as very promising
solution, particularly, for some special tasks (i.e., modeling the
developing BBB, assessment of BBB permeability corresponding
to the neonatal period etc.). This direction is further actualized
while thinking about microphysiological systems reflecting basic
properties of biological tissues and organs in the miniature scale.
It is now possible to see the increasing significance of
the knowledge of EPC contribution to BBB development and
functioning in the context of microphysiological systems (MPS).
MPS are the complex in vitro models of tissues and organs
(combination of so-called “organoids”) aimed to establish their
functional interrelations. In most the cases, it is the next step after
the application of microfluidic technologies to the reconstruction
of “organ-on-chip” or “body-on-chip” in the microenvironment
close to the real one. Moreover, “physiome-on-chip” concept
(Stokes et al., 2015) could bemore beneficial in obtaining relevant
physiological data using MPS approach.
It should be mentioned that microfluidics has influenced
BBB modeling in vitro a lot: several successful attempts to
establish functional BBB on the microfluidic platform have been
reported (Booth and Kim, 2012; Griep et al., 2013; Cho et al.,
2015). At the same time, there is also increasing interest in the
utilization of stem cells-derived material for BBB constructing
in vitro: development of astrocytes and neurons from neural
progenitor cells (Lippmann et al., 2011; Khilazheva et al., 2015),
development of BMEC from induced pluripotent stem cells
(Lippmann et al., 2012), or even establishment of the barrier from
BMEC and neural stem cells in vitro (Chou et al., 2014).
Complementary properties of both these approaches will
make possible the reconstruction of stem cells-derived cell
components of NVU/BBB in the improved microenvironment
like it was recently suggested for “brain-on-chip” technologies
(Alcendor et al., 2013; van der Helm et al., 2016) applicable for
effective in vitro drug screening. In this context, reconstruction
of brain microvasculature in a flow-directed MPS is one of the
topic question which might be solved using EPC as not only a
source of BMEC, but also as informative monitoring system to
study angiogenesis/barriergenesis “on-line.”
Frontiers in Physiology | www.frontiersin.org 9 December 2016 | Volume 7 | Article 599
Malinovskaya et al. Blood-Brain Barrier and Endothelial Progenitor Cells
TABLE 1 | Key metabolic properties of EPC, EC/BMEC.
EPC EC, BMEC
Basal glycolytic rate and lactate production High High, particularly in phalanx and stalk cells
Glycolytic rate and lactate production upon stimulatory
conditions (expansion, mobilization, migration)
Elevated (not more than 2-fold) Elevated in tip and stalk cells, suppressed when
branching is reduced
Mitochondrial number and OXPHOS intensity Low mitochondrial mass, immature
mitochondrial morphology; low OXPHOS
High mitochondrial mass in BMEC comparing to EC in
other tissues; OXPHOS is less notable than glycolysis
Mitochondrial number and OXPHOS intensity upon
stimulatory conditions (expansion, mobilization,
migration)
Up-regulated Up-regulated
Mitochondrial ROS production upon basal and
stimulatory conditions (expansion, mobilization,
migration)
Up-regulated upon EPC stimulation but the
antioxidant activity is high
Low in quiescent cells but up-regulated in branching
angiogenesis
Utilization of ketone bodies High High at the earliest stages of ontogenesis
Fatty acid oxidation Relatively low, elevated in stimulatory conditions High, particularly in low glucose conditions
Pentose phosphate pathways activity Low High
Lactate-mediated effects Stimulates migration and differentiation Stimulates angiogenesis
Physiological and biochemical heterogeneity High Low
Based on the integrated data presented in Oldendorf et al., 1977; Dernbach et al., 2004; Milovanova et al., 2008b; Fraisl et al., 2009; Freeman and Keller, 2012; De Bock et al., 2013;
Goligorsky, 2014; Harjes et al., 2014; Tang et al., 2014; Xu et al., 2014; Salmina et al., 2015; Schoors et al., 2015.
So, what are the possible advantages in the application of
EPC for NVU/BBB modeling in vitro and MPS designing?
Establishment of vessel networks at the microfluidic platform
and in MPS is performed by seeding EC (usually HUVEC, or
BMEC if BBB model is reconstructing) as well as accessory cells,
(i.e., pericytes or astrocytes) within the chamber channels. To
provide efficient endothelial proliferation and vessel sprouting,
chemical gradient of pro-angiogenic factors (i.e., VEGF) can
be settled in the close vicinity to the growing vessel (Sakolish
et al., 2016). Dynamic fluid flow mimics the conditions achieved
in the real BBB and allows controlling in vivo-like vessel
barriergenesis. In a case of BMEC, BBB-specific phenotype of
the cells is one of the critical factors for proper modeling the
barrier or its functional connection with other tissues/organoids
within the MPS (Alcendor et al., 2013). Therefore, the following
physiological and metabolic parameters of EPC or BMEC should
be taken into the consideration in BBB models or MPS: (i) ability
to establish functionally competent monolayer with BBB-specific
properties (selective permeability, tight junction connections,
expression of specific receptors and transporters) reproducible
in either static or microfluidic conditions; (ii) high sensitivity
to the action of pro-angiogenic stimuli (VEGF, MMP, lactate
etc.) produced by surrounding cells; (iii) dynamic changes in cell
metabolism upon action of glia-, pericyte-, or neuron-derived
signals; (iv) ontogenesis-related changes in cell metabolism; (v)
expression of molecules critical for CNS homing and acquisition
of BBB-specific phenotype; (vi) ability to support neurogenesis
within the neurogenic niches in vitro.
Translational prospects of BBB models in vitro or BBB-
on-chip technologies dictate the urgent interest in selecting
the most appropriate EC whose growth and functional activity
would be relevant for in vitro testing and drug candidates and
assessment of BBB disruption in various CNS disorders. Thus,
application of EPC would be beneficial for the controlled growth
of brain microvessel-like structures in the conditions close to the
BBB microenvironment in order to facilitate further studies of
NVU/BBB or cerebrovascular (patho)physiology (Cucullo et al.,
2013), particularly, at early stages of ontogenesis. Also, EPC
would overcome the problem of human brain microvascular
cells availability for BBB modeling or MPS in vitro. Currently,
few BBB models in vitro utilize human endothelial cells, and
this problem hampers progress in preclinical pharmacological
studies (Pamies et al., 2014). Human induced pluripotent
stem cells are tested as a source of NVU components not
only in the static BBB models (Lippmann et al., 2012) but
also for the microfluidics-based technological solutions (Brown
et al., 2015). Microfluidic approach might be also used for
specific and efficient capture of EPC from the peripheral
blood as it was demonstrated in cardiovascular bioengineering
(Plouffe et al., 2009; Lin et al., 2015a). Then, development of
“user friendly” protocols for in vitro differentiation of EPC
obtained from the bone marrow or peripheral blood into
BMEC, and for the establishment of NVU microenvironment
supporting EPC integration in the growing microvessels would
give us an opportunity to establish fully functioning endothelial
layer with BBB characteristics. Solving these technological
questions would provide novel engineering approaches toward
controlling brain developmental and pathological angiogenesis,
improved microfluidically-supported BBB models and/or brain
multicompartment MPS suitable for translational studies in
neurology and neuropharmacology.
CONCLUSION
Metabolic and functional plasticity of EPC controls their timely
recruitment, precise homing to the brain microvessels, and
efficient support of brain angiogenesis. Being under the control
of numerous regulatory factors, EPC serve as a source of BMEC
with BBB specific characteristics in the developing brain. In the
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adult brain, EPC contribute (directly or as a source and carrier of
pro-angiogenic factors) to BBB re-endothelialization upon injury
or to the cerebral angiogenesis associated with physiological
conditions (i.e., activity-induced neurogenesis) or pathological
conditions (i.e., tumor progression). A key challenge in the field
of EPC physiology is the current shortage of the knowledge on
the most efficient ways to manipulating their activity both in vitro
and in vivo. However, solving this problem would be beneficial
for the therapy of cerebrovascular diseases, brain trauma,
neurodegeneration, brain tumors, and neuroinfection. Metabolic
activity and functionality of EPC differs from those of BMEC and
is tightly regulated by numerous systemic and local factors at all
the steps of EPC development. Accumulating evidence suggests
that further progress in studying BBB (patho)physiology,
establishment of new therapeutic methods for reversible and
controlled BBB opening, or designing the new in vitro assays
for drug development (BBB models or microphysiological
constructions) critically depends on deciphering molecular and
biochemical mechanisms underlying EPC functional role in
the developmental, pathological, and plasticity-driven cerebral
angiogenesis.
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